KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

27.00 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about KalVista Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Expert Ratings for KalVista Pharma ↗

October 05, 2022

KalVista Pharma (NASDAQ:KALV) has observed the following analyst ratings within the last quarter:

Via Benzinga

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 05, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Why KalVista Pharmaceuticals Shares Are Trading Lower By 59%; Here Are 89 Biggest Movers From Yesterday ↗

October 05, 2022

Losers

Via Benzinga

S&P 500 Rises 100 Points; Nasdaq Up 3% ↗

October 04, 2022

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing more than 300 points on Tuesday.

Via Benzinga

Why Is KalVista Pharmaceuticals (KALV) Stock Down 50% Today? ↗

October 04, 2022

KALV stock investors are having a hard day as KalVista Pharmaceuticals just hit the brakes on a crucial clinical study.

Via InvestorPlace

KalVista Shares Plunge After Ending KVD824 HAE Trial Over Elevated Liver Enzymes In Patients ↗

October 04, 2022

Via Benzinga

KalVista Pharma: Q1 Earnings Insights ↗

September 08, 2022

KalVista Pharma (NASDAQ:KALV) reported its Q1 earnings results on Thursday, September 8, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

October 05, 2022

Wednesday saw 127 companies set new 52-week lows.

Via Benzinga

Where KalVista Pharma Stands With Analysts ↗

October 05, 2022

Analysts have provided the following ratings for KalVista Pharma (NASDAQ:KALV) within the last quarter:

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 04, 2022

Gainers

Via Benzinga

Kalvista Crashes Nearly 60% After Adding HAE Drug To The Scrap Heap ↗

October 04, 2022

The company scrapped its hereditary angioedema drug due to safety issues.

Via Investor's Business Daily

Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session ↗

October 04, 2022

Gainers Bit Brother Limited (NASDAQ: BTB) rose 229% to $0.3688 after declining around 14% on Monday.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

October 04, 2022

On Tuesday, 44 companies hit new 52-week lows.

Via Benzinga

Nasdaq Surges 350 Points; Crude Oil Rises Sharply ↗

October 04, 2022

U.S. stocks traded higher midway through trading, with the Nasdaq Composite climbing more than 350 points on Tuesday.

Via Benzinga

FaZe Holdings, AXT And Some Other Big Stocks Moving Lower On Tuesday ↗

October 04, 2022

U.S. stocks traded higher, with the Dow Jones gaining more than 700 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

US Stocks Open Higher As Dow Jumps 550 Points ↗

October 04, 2022

U.S. stocks traded higher this morning, with the Dow Jones climbing more than 550 points on Tuesday.

Via Benzinga

Why Kalvista Pharmaceuticals Shares Are Down Over 50% ↗

October 04, 2022

Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares are trading lower by 52.42% to $6.78 Tuesday morning after the company announced it terminated the KOMPLETE phase 2 clinical trial for KVD824 for the...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 04, 2022

Gainers Avenue Therapeutics (NASDAQ:ATXI) shares moved upwards by 37.7% to $15.85 during Tuesday's pre-market session. The company's market cap stands at $23.3 million.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

October 04, 2022

Good morning, investor! It's time for a breakdown of the biggest pre-market stock movers traders need to know about for Tuesday!

Via InvestorPlace

KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema

October 04, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present at the 2022 HAEi Global Leadership Workshop

September 30, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports First Fiscal Quarter Results

September 08, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 02, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary ↗

August 23, 2022

Via Benzinga

KalVista Shares Climb As Late-Stage Label Extension Study On Skin Disorder Candidate Kicks-off ↗

August 23, 2022

KalVista Pharmaceuticals (NASDAQ: KALV) has initiated the KONFIDENT-S open label extension (OLE) study for its ongoing Phase 3 study of sebetralstat for the on-demand treatment of hereditary angioedema...

Via Benzinga

KalVista Pharmaceuticals Announces Initiation of KONFIDENT-S Open Label Extension Study for Sebetralstat in Hereditary Angioedema

August 23, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Why Pharvaris Stock Crashed — And Why At Least One Analyst Isn't Worried ↗

August 22, 2022

Shares hit their lowest point since November on the FDA's decision in HAE.

Via Investor's Business Daily

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 02, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present at 1st Annual H.C. Wainwright Hereditary Angioedema Conference

July 19, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Recap: KalVista Pharmaceuticals Q4 Earnings ↗

July 07, 2022

KalVista Pharmaceuticals (NASDAQ:KALV) reported its Q4 earnings results on Thursday, July 7, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.